Clinical Trials Logo

Phenylketonurias clinical trials

View clinical trials related to Phenylketonurias.

Filter by:

NCT ID: NCT01541397 Terminated - Phenylketonuria Clinical Trials

Bone Mineral Density in Adults With Hyperphenylalaninemia on Kuvan Therapy

Start date: June 2011
Phase: N/A
Study type: Interventional

Prospective study to compare the bone mineral density in adults with HPA on KUVAN™ therapy to those not on therapy. The investigators hypothesize that after one year of KUVAN™ therapy, there will be an improvement in their bone mineral density.

NCT ID: NCT01465100 Terminated - Phenylketonuria Clinical Trials

Liver Cell Transplant for Phenylketonuria

Start date: October 12, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Human phenylketonuria (PKU) results from phenylalanine hydroxylase (PAH) deficiency, and represents one of the most common and extensively studied single-gene Mendelian disorders in humans. Unfortunately, optimum clinical outcome demands lifelong dietary restriction through adherence to an unpalatable and expensive artificial diet. Challenges in maintaining traditional therapy lead to increasing phenylalanine (Phe) levels in patients as they approach adulthood with an incumbent severe burden of psychosocial and intellectual difficulties. The recent introduction of the new medication Sapropterin for treatment of PKU has improved Phe control and dietary tolerance in some patients, but at enormous cost to patients and insurers for the FDA designated orphan product. Thus, there is an unmet need for novel therapies to correct PKU. PAH is almost exclusively expressed in the liver in humans. The main objective of the current proposal is to examine the safety and efficacy of hepatocyte transplantation in patients with PKU.

NCT ID: NCT01395394 Terminated - Phenylketonuria Clinical Trials

Phenylketonuria, Oxidative Stress, and BH4

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see how tetrahydrobiopterin therapy (BH4; also known as sapropterin dihydrochloride or Kuvan) affects measures of oxidative stress and endothelial function in patients with Phenylketonuria (PKU).

NCT ID: NCT00827762 Terminated - Phenylketonuria Clinical Trials

Behavioral Effects of Kuvan in Children With Mild Phenylketonuria

Start date: January 2009
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether improvements in behavior occur in children with phenylketonuria (PKU) who are taking Kuvan.

NCT ID: NCT00432822 Terminated - Clinical trials for Phenylalanine Hydroxylase Deficiencies

Long-Term Tetrahydrobiopterin Treatment in PKU Patients of 0-18 Years - Study on Phenylalanine Tolerance and Safety

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of the study is to confirm the efficacy and safety of BH4 in the treatment of hyperphenylalaninemia caused by phenylalanine hydroxylase deficiency in patients responsive to BH4. The primary objective is to assess the effect of BH4 on phenylalanine tolerance compared to placebo under optimal blood phenylalanine control and to demonstrate safety in 12 months long-term treatment. Additionally population PK will be assessed.

NCT ID: NCT00244218 Terminated - Phenylketonuria Clinical Trials

Response to Phenylketonuria to Tetrahydrobiopterin (BH4)

Start date: April 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether tetrahydrobiopterin (BH4)is effective in treating patients with PKU.